EUVIMEDEUVIMED entdecken
Crossref

Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation

Minori Teraguchi, Toshiaki Komatsu, Yuto Akamada, Takeru Nabeta, Hidehira Fukaya, Junya Ako, Katsuya Otori

Clinical Drug Investigation · 2026-09 · 46 (9) · 1037-1045

DOI: 10.1007/s40261-026-01574-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 22.06.2026. Verfasst von Minori Teraguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan. Hauptthemen laut MEDLINE: Amiodarone, Machine Learning, Anti-Arrhythmia Agents, Lung Diseases, Interstitial. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: The accumulation of N-desethylamiodarone (DEA), an active metabolite of amiodarone, is a recognized risk factor for interstitial pneumonia. However, predictors of DEA accumulation, particularly during the initiation phase of amiodarone therapy, remain unclear. We aimed to identify predictors of DEA accumulation using classification and regression tree analysis and to verify their association with interstitial pneumonia in patients receiving amiodarone. METHODS: We conducted a retrospective analysis of 80 patients who underwent therapeutic drug monitoring of amiodarone and DEA levels at Kitasato University Hospital. Potential risk factors for elevated DEA levels (≥ 0.6 mg/L) were identified using classification and regression tree analysis with 20 variables. To prevent overfitting, strict pruning parameters were implemented (minimum bucket size = 7, maximum depth = 2). N-desethylamiodarone levels were compared between patients with and without interstitial pneumonia, and the findings were validated through Monte Carlo simulations based on published pharmacokinetic models. RESULTS: Elevated DEA levels (≥ 0.6 mg/L) were observed in 23 patients (29%). Classification and regression tree analysis identified treatment duration (cutoff: 47 days) and weight-adjusted dose (cutoff: 2.15 mg/kg/day) as primary determinants of DEA accumulation (accuracy: 0.88; area under the curve: 0.90 [95% confidence interval 0.84-0.95]). Among the five patients who developed interstitial pneumonia, four (80%) exhibited elevated DEA levels, compared to 19 of 75 (25%) patients without interstitial pneumonia (p = 0.022). Pharmacokinetic simulations confirmed that the probability of toxic DEA accumulation increases substantially at doses exceeding 150 mg/day. CONCLUSIONS: Treatment duration (≥ 47 days) and weight-adjusted dose (≥ 2.15 mg/kg/day) are significant predictors of DEA accumulation in this cohort of Japanese patients. Elevated DEA levels are significantly associated with the onset of interstitial pneumonia. To minimize the risk of toxicity, taking a maintenance dose of ≤ 100 mg/day (or < 2.15 mg/kg/day, which corresponds to ≤ 100 mg/day for a standard 50-kg patient) and monitoring DEA levels are recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneMachine LearningAnti-Arrhythmia AgentsLung Diseases, InterstitialHumansRetrospective StudiesFemaleMaleAgedMiddle AgedDrug MonitoringMonte Carlo MethodAged, 80 and overComputer SimulationRisk Factors

Substanzen

AmiodaronedesethylamiodaroneAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan.
  • Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan. t.komatu@kitasato-u.ac.jp.
  • Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
  • Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, Sagamihara, Kanagawa, Japan.

Zitieren

APA

Teraguchi, M., Komatsu, T., Akamada, Y., Nabeta, T., Fukaya, H., Ako, J., & Otori, K. (2026). Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation. Clinical Drug Investigation, 46(9), 1037-1045. https://doi.org/10.1007/s40261-026-01574-8

Vancouver

Teraguchi M, Komatsu T, Akamada Y, Nabeta T, Fukaya H, Ako J, et al. Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation. Clinical Drug Investigation. 2026;46(9):1037-1045. doi:10.1007/s40261-026-01574-8

BibTeX
@article{Teraguchi2026,
  author = {Teraguchi, Minori and Komatsu, Toshiaki and Akamada, Yuto and Nabeta, Takeru and Fukaya, Hidehira and Ako, Junya and Otori, Katsuya},
  title = {Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {9},
  pages = {1037--1045},
  doi = {10.1007/s40261-026-01574-8}
}
Kostenlos starten →